Showing results (211-220 of 306) with videos related to
Sort By:
Pageof 31
Gynecologic Oncology|February 22, 2011
Significance of numbers of metastatic and removed lymph nodes in FIGO stage IB1 to IIA cervical cancer: Primary surgical treatment versus neoadjuvant chemotherapy before surgeryHee Seung Kim, Ji Hyun Kim, Hyun Hoon Chung, et al.Annals of the New York Academy of Sciences|September 3, 2009
Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancerHee Seung Kim, Sok-Bom Kang, Sang-Soo Seo, et al.Annals of Surgical Oncology|November 4, 2008
Matched-case comparison for the role of surgery in FIGO stage Ib1-IIa squamous cell carcinoma of cervix and suspicious para-aortic lymph node metastasisHee Seung Kim, Noh Hyun Park, Hong Gyun Wu, et al.Cancer Research and Treatment|November 18, 2021
Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of ChemotherapyAeran Seol, Ga Won Yim, Joo Yeon Chung, et al.Japanese Journal of Clinical Oncology|November 1, 2019
An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITIONJung-Yun Lee, Ju Yeon Yi, Hyun-Soo Kim, et al.Gynecologic Oncology|January 16, 2019
Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancerSe Ik Kim, Jae Hyun Cho, Aeran Seol, et al.BMC Cancer|May 3, 2018
LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas dataSe Ik Kim, Ji Won Lee, Nara Lee, et al.Anticancer Research|December 31, 2021
The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based StudyEun Ji Lee, Soo Jin Park, Jeesun Lee, et al.Journal for Immunotherapy of Cancer|October 21, 2023
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-DJunsik Park, Jung Bok Lee, Myong Cheol Lim, et al.Gynecologic Oncology|September 3, 2023
Clinical implications of histologic subtypes on survival outcomes in primary mucinous ovarian carcinomaHyunji Lim, Yiyoung Ju, Se Ik Kim, et al.Pageof 31